Xenikos
OverviewSuggest Edit
Xenikos is a clinical-stage biopharmaceutical company. It develops immunotherapies based on the action of toxin-conjugated antibodies for patients suffering immune diseases, or rejection after transplantation.
| Type | Private | |
| Founded | 2012 | |
| HQ | Nijmegen, NL | Map |
| Website | xenikos.com |
Latest Updates
| Employees (est.) (Jul 2021) | 13 | |
| Cybersecurity rating | A | More |
Key People/Management at Xenikos
Ypke van Oosterhout
Founder and Chief Executive Officer, Director
Douglas E. Williams
Chairman of the Board, Non-Executive Director
Maarten Frijlink
Chief Operating Officer
Jake Simson
Non-Executive Director
Eric van Hooren
Chief Development Officer
Viktor Mattousch
Board Observer
Xenikos Office Locations
Xenikos has an office in Nijmegen
Nijmegen, NL (HQ)
Wilhelminasingel 14
Xenikos Financials and Metrics
Summary Metrics
Founding Date | 2012 |
Xenikos total Funding | $37 m |
Xenikos latest funding size | $30 m |
Time since last funding | 3 years ago |
Xenikos investors | RA Capital Management, Medicxi Ventures, OostNL, Agentschap NL, Innovation & Investment Fund Gelderland, Sanquin Blood Supply Foundation |
Xenikos's latest funding round in May 2018 was reported to be $30 m. In total, Xenikos has raised $37 m
Xenikos Cybersecurity Score
Xenikos Online and Social Media Presence
Xenikos's Trends
Xenikos News and Updates
July 19, 2021
Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021
Xenikos Blogs
July 19, 2021
Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
Het bericht Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives verscheen eerst op Xenikos - Resetting the immune system.
Xenikos Frequently Asked Questions
When was Xenikos founded?
Xenikos was founded in 2012.
Who are Xenikos key executives?
Xenikos's key executives are Ypke van Oosterhout, Douglas E. Williams and Maarten Frijlink.
How many employees does Xenikos have?
Xenikos has 13 employees.
Who are Xenikos competitors?
Competitors of Xenikos include Pliant Therapeutics, Rome Therapeutics and Quellis Biosciences.
Where is Xenikos headquarters?
Xenikos headquarters is located at Wilhelminasingel 14, Nijmegen.
Where are Xenikos offices?
Xenikos has an office in Nijmegen.
How many offices does Xenikos have?
Xenikos has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies